Brief: Paradigm Biopharmaceuticals Initiates Phase 3 Clinical Trial In Knee Osteoarthritis Across The U.S
17/03/2022 17:28
March 17 (Reuters) - Paradigm Biopharmaceuticals Ltd
PAR.AX :
* PARADIGM BIOPHARMACEUTICALS INITIATES A PHASE 3 CLINICAL
TRIAL
IN KNEE OSTEOARTHRITIS ACROSS THE U.S
Source text for Eikon: ID:nPn7F3VNXa
Further company coverage: PAR.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paradigm Biopharmaceuticals
See all newsBrief: Paradigm Biopharmaceuticals Says Board Initiates Voluntary Administration
Brief: Paradigm Biopharmaceuticals Seeks Trading Halt
Australia's Paradigm Biopharmaceuticals slips on discounted placement
Brief: Paradigm Biopharmaceuticals Says Co Completes A$14 Mln Placement
Brief: Paradigm Biopharmaceuticals Requests Trading Halt